Zolbetuximab Alternatives Compared
| Zolbetuximab | Ogivri (trastuzumab) | Taxotere (docetaxel) |
|
|---|
| Zolbetuximab | Ogivri (trastuzumab) | Taxotere (docetaxel) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Gastric Cancer. Zolbetuximab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer - Adjuvant, Esophageal Carcinoma, Breast Cancer, Gastric Cancer. Ogivri may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Prostate Cancer, Breast Cancer, Gastric Cancer, Breast Cancer - Metastatic, Non Small Cell Lung Cancer, Head and Neck Cancer. Taxotere may also be used for purposes not listed in this... View more |
Related suggestions Gastric Cancer
|
|||||||
| More about Zolbetuximab | More about Ogivri (trastuzumab) | More about Taxotere (docetaxel) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Taxotere has an average rating of 5.2 out of 10 from a total of 11 ratings on Drugs.com. 36% of reviewers reported a positive effect, while 45% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Zolbetuximab side effects |
View all Ogivri side effects |
View all Taxotere side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ogivri prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
|
||||||||
| Brand Names | ||||||||||
| Vyloy | Other trastuzumab brands include: Herceptin, Hercessi, Herzuma, Kanjinti, Ontruzant, Trazimera | Other docetaxel brands include: Docivyx | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
984 hours |
924 hours |
11.1 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 143 drugs are known to interact with Zolbetuximab:
|
A total of 192 drugs are known to interact with Ogivri:
|
A total of 521 drugs are known to interact with Taxotere:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
October 18, 2024 |
December 01, 2017 |
May 14, 1996 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.